Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.72 |
| ▸ | CA1 | P00915 | 6/20 | 0.72 |
| ▸ | CA2 | P00918 | 6/20 | 0.72 |
| ▸ | CA7 | P43166 | 6/20 | 0.72 |
| ▸ | CA9 | Q16790 | 6/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.72 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337806 | 0.86 | ESR1 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28417178 | 0.86 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8284386 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL39791 | 0.84 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29625511 | 0.84 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14841131 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26586723 | 0.83 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| Water SCHEMBL16678551 | 0.82 | CA12 (0.96) | CA12CA1CA2CA7CA9 | |
| SCHEMBL190407 | 0.82 | CA12 (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3666786 | 0.81 | LMNA (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3890738-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | Scohia Pharma, Inc. (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113164468-A | Macrocyclic compounds and uses thereof | 思可海雅药品公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| EP-3225618-B1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| EP-1593666-A1 | AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1539158-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004006922-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| EP-0938483-B1 | MUSCARINIC ANTAGONISTS | SCHERING CORP (US) | 2003-02-26 | — | — | EP | disclosed |
| CN-1084743-C | Muscarinic antagonists | SCHERING CORP (US) | 2002-05-15 | — | — | CN | disclosed |
| CN-1232462-A | Muscarinic antagonists | SCHERING CORP (US) | 1999-10-20 | — | — | CN | disclosed |
| EP-0938483-A2 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998005292-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE AS MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | TFAM, KEAP1, FASTKD1 | CA12 4266/4885CA1 4500/4885CA2 4163/4885 |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | TFAM, KEAP1, CKMT1A; CKMT1B | CA12 4263/4885CA1 4436/4885CA2 4132/4885 |
| US-20060052384-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | LDLR, NR1H2, NR1H3 | CA12 4883/4885CA1 4881/4885CA2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.